Global private equity and venture capital news and research

Apple Tree Partners leads $25m Tendyne Series C round

10 Apr 2014

heart_lrgPharmaceutical and healthcare-focused venture capital firm Apple Tree Partners has led a $25m Series C financing round for medical device business Tendyne.

Apple Tree partner David McIntyre will join the board of directors at Tendyne, which makes devices to prevent blood leaking into a valve in the heart.

Tendyne founder and CEO Jeff Franco said, “This financing is a significant milestone for Tendyne.

“In 2013 Tendyne demonstrated positive human data and this infusion of capital allows us to move ahead confidently as we accelerate our minimally invasive mitral valve program.

“We are excited to have Apple Tree Partners come on board. We look forward to benefiting from their experience as we develop our technology and clinical presence.”

Last year Apple Tree backed a $35m Series E round for cancer-focused biotech company Tokai Pharmaceuticals.

That funding was slated to be used to develop Tokai’s lead prostate cancer candidate.

Copyright © 2014 AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016